DiaGenic ASA is an innovative Norwegian life sciences company founded in 1998 and listed on the Oslo Stock Exchange.

DiaGenic develops patient-friendly tests for the early diagnosis of devastating diseases where early intervention is crucial for successful treatment. DiaGenic’s patented tests are based on the identification and clinical documentation of disease-specific gene expression signatures measured in blood samples. The first two are for the early diagnosis of breast cancer and Alzheimer’s disease (BCtect® and ADtect®) and were already CE marked in June 2009.

In response to growing demand, DiaGenic is now making its technology widely available to pharmaceutical and other companies with interests in CNS. Using either own or the client’s proprietary biobank, DiaGenic can develop unique biomarker tests to accelerate patient recruitment and monitor response in clinical trials. DiaGenic can then further develop companion diagnostics for candidate drugs.